![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
JT Turner, DW Bollinger and ML Toews
Department of Pharmacology, School of Medicine, University of Missouri- Columbia.
In this study we have characterized and compared the regulation of the HT29 cell vasoactive intestinal peptide receptor/adenylate cyclase system (VIP-R/AC) by the VIP-R agonist peptide histidineisoleucineamide (PHI) and by activators of protein kinase C (PKC) including phorbol 12- myristate, 13-acetate (PMA) and mezerein. Preincubation with either PHI or PKC activator decreased maximum VIP-stimulated AC activity and decreased the number of cell surface VIP-R. A [125I]VIP binding assay using solubilized VIP-R of the plasma membrane and light vesicle fractions from sucrose density step gradients was developed as a more direct measure of VIP-R internalization. Preincubation with PHI or PMA decreased plasma membrane fraction [125I]VIP binding and increased binding in the light vesicle fraction, thus providing the most direct evidence to date for translocation of VIP-R per se from the plasma membrane to another, presumably intracellular, compartment. Two experimental approaches differentiated between agonist and PKC activator regulation of VIP-R/AC. The protein kinase inhibitors H-7 and staurosporine blocked mezerein-, but not PHI-, induced losses of cell surface VIP-R. Also, down-regulation of PKC did not block PHI-induced loss of cell surface VIP-R. Thus, although both agonist and PKC activators can lead to desensitization and internalization of VIP-R, PKC is apparently not involved in the mechanisms of agonist-induced desensitization.
This article has been cited by other articles:
|
|
 |
|
  T. Ikegami, L. Krilov, J. Meng, B. Patel, K. Chapin-Kennedy, and B. Bouscarel Decreased Glucagon Responsiveness by Bile Acids: A Role for Protein Kinase C{alpha} and Glucagon Receptor Phosphorylation Endocrinology, November 1, 2006; 147(11): 5294 - 5302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Lara-Marquez, M. S. O'Dorisio, T. M. O'Dorisio, M. H. Shah, and B. Karacay Selective Gene Expression and Activation-Dependent Regulation of Vasoactive Intestinal Peptide Receptor Type 1 and Type 2 in Human T Cells J. Immunol., February 15, 2001; 166(4): 2522 - 2530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Akiyama, Y. Hirohata, Y. Okabayashi, I. Imoto, and M. Otsuki Supramaximal CCK and CCh concentrations abolish VIP potentiation by inhibiting adenylyl cyclase activity Am J Physiol Gastrointest Liver Physiol, November 1, 1998; 275(5): G1202 - G1208. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
